SALBUTAMOL, Trimbow 172 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution clinical trials

A 12-week double-blind, multicentre, randomised, active-controlled, 2-arm, parallel-group clinical trial to evaluate the safety of CHF5993 pMDI 200/6/12.5 µg HFA-152a, compared to CHF5993 pMDI 200/6/12.5 µg HFA-134a, in subjects with asthma

This study is testing a new version of an asthma inhaler (CHF5993) to see if it's safe for people aged 18 and over with moderate to severe asthma. It compares the new version against an existing one over 12 weeks to ensure it works just as well and has similar side effects.